Waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder. It usually affects older adults and is primarily found in the bone marrow . Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity demonstrating lymphoplasmacytic lymphoma (LPL) in the bone. Waldenström macroglobulinemia is often an indolent disorder, and many patients are candidates for observation with careful monitoring.
|Published (Last):||18 July 2009|
|PDF File Size:||5.32 Mb|
|ePub File Size:||19.25 Mb|
|Price:||Free* [*Free Regsitration Required]|
June 04, ; Accepted: WM is characterized by having high levels of a circulating antibody, immunoglobulin M IgMwhich is made and secreted by the cells involved in the disease.
The detection of IgM monoclonal gammopathy is important for diagnosis, but the serum concentration presents a great variability between individuals. Lymphocytes are small or medium in size with irregular nucleus.
Flow cytometry may be used to examine markers on the cell surface or inside the lymphocytes. It is fundamental to distinguish WM from other disorders that could wladenstrom clinically confused with this disease. A bone marrow biopsy provides a sample of bone marrow, usually from the back of the pelvis bone.
Monoclonal IgM may exhibit “cold agglutinin” activity, binding to erythrocyte antigens at a temperature lower than physiological temperature, determining the development enfermevad chronic cold antibody hemolytic anemia.
There are genetic factorswith first-degree relatives of WM patients shown to have a highly increased risk of also developing the disease. Signs and symptoms of WM include weakness waldensyrom, fatigueweight lossand chronic oozing of blood from the nose and gums.
Waldenström’s macroglobulinemia – Wikipedia
The assessment of the clinical status of patients involves several examinations and laboratory tests Table 2. Some of these markers are particularly useful for studying the bone marrow infiltrate in the enfermmedad biopsy through immunohistochemical and other studies for the immunophenotypic characterization of B-lymphocytes by flow cytometry.
The clinical presentation of WM varies. Useful in patients with Raynaud’s syndrome, acrocyanosis or limb ulceration. Paradoxical increases wqldenstrom serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemia.
Patients with findings of peripheral neuropathy should have nerve conduction studies and antimyelin associated glycoprotein serology. Cancer Management and Research. International Journal of Laboratory Hematology. Macroglobulinosis cutis revealing Waldenstrom macroglobulinemia. Prognostic factors in symptomatic Waldenstrom’s macroglobulinemia.
In fact, the choice of treatment is a critical option and should not be taken so as to limit future options, since all patients will inevitably present relapses after initial treatment, requiring treatment. Current medical treatments result in survival of enfermmedad longer than 10 years; in part this is because better diagnostic testing means early diagnosis and treatments.
Detection of monoclonal enfermeda – homogeneous peak, high, narrow base, usually in the area of gamma globulins. Curr Treat Options Oncol.
WM was first described by Jan G. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Treatment includes the monoclonal antibody rituximabsometimes in combination with chemotherapeutic drugs such as chlorambucilcyclophosphamideor vincristine or with thalidomide. Archives of Internal Medicine. Complications such as hyperviscosity syndrome, symptomatic sensorimotor peripheral neuropathy, systemic amyloidosiskidney failureor symptomatic cryoglobulinemia were also suggested as indications for therapy.
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Rare cancers Hematologic malignant neoplasms Vascular-related cutaneous conditions Lymphoma.
Immunoproliferative immunoglobulin disorders D89 IgA and Waldenstro, hypogammaglobulinemia in Waldenstrom’s macroglobulinemia. Del 6q and Del 17p – Genetic alterations associated with clinical progression of the disease.
Haematologica ;92 6 suppl 2: Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenstrom’s macroglobulinemia. Rituximab is an IgG1 anti-CD20 monoclonal antibody.
Comparative genomic hybridization identified the following chromosomal abnormalities: Neuropathies associated with paraproteinemia.
This page was last edited on 20 Decemberat Transplantation of hematopoietic stem cells is indicated in younger patients with multiple recurrences or who have been refractory to previous treatments. The ESR and uric acid level may be elevated. In patients with relapse or refractory to therapy, autologous transplantation may be indicated.
Immunophenotypic variations may occur. The WM is a rare disease with a typically indolent clinical course, affecting mainly individuals aged between 63 and 68 years.
Should treatment be started it should address both the paraprotein level and the lymphocytic B-cells. Subsequent treatment should be started quickly, as the concentration of IgM will return to its initial level after 4 to 5 weeks. Pruzanski W, Shumak KH. The infiltration of malignant cells in the central nervous system is responsible for a rare neurological disorder called Bing-Neel syndrome. Both cell types are white blood cells.
Waldenström’s macroglobulinemia – a review
Bing and Neel syndrome. Other factors may contribute to its aggravation, such as gastrointestinal bleeding, hyperhemolysis, and hyperviscosity itself, which may cause a decrease in the erythropoietin synthesis.
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenstrom’s macroglobulinemia.